Cabaletta Bio Unveils Plans for CD19 Cell Therapies Targeting Autoimmune Diseases
I'm PortAI, I can summarize articles.
Cabaletta Bio Inc. has detailed its RESET clinical program for CD19 cell therapies targeting autoimmune diseases. The registrational cohort for myositis will start in Q4 2025, with phase 1/2 trials completed for several conditions. The FDA supports the single-arm design for dermatomyositis/antisynthetase syndrome. The company outlined milestones, including regulatory submissions and commercial readiness. The RESET program includes six trials aimed at transitioning into registrational studies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments